We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGain Therapeutics Inc

Gain Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.03 USD -0.08 ( 7.21%)
Last update at 2026-11-12T15:36:00Z
VOLUME
80371
Market Cap
74.63M

Momentum Score

…

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.01
Low
1.08
High
52 Week Price Range
1.53
Low
4.34
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Gain Therapeutics is a clinical-stage biotechnology company that applies a computational allosteric drug discovery platform to develop precision small-molecule therapies that modulate protein conformational dynamics. Long-term growth drivers include advancing pipeline candidates through clinical trials, platform outputs and potential partnerships or licensing. Investors may find it attractive because the platform could support differentiated candidates addressing unmet medical needs.

Principal investment risks are clinical and regulatory setbacks, high cash burn with likely need for additional funding and competition from larger pharmaceutical companies or alternative modalities.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.11
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-9.99M
Debt / Equity
0.04
ROE
-268.30%
Net Debt
-20.11M
ROCE
-96.12%
Diluted EPS TTM
-0.49

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -19.30M -19.87M -22.19M -17.50M -13.89M
Net income -20.16M -20.41M -22.27M -17.59M -13.89M
Selling general administrative 8.50M 9.56M 10.79M 9.54M 6.83M
Selling and marketing expenses - - 0.05M - -
Gross profit -0.09M -0.08M 0.06M 0.14M 0.16M
Reconciled depreciation 0.09M 0.08M 0.08M 0.06M 0.02M
Ebit -18.71M -20.35M -22.25M -17.78M -13.83M
Ebitda -18.62M -20.27M -22.17M -17.68M -13.75M
Depreciation and amortization 0.09M 0.08M 0.08M 0.10M 0.07M
Non operating income net other - - - -0.10M -
Operating income -18.71M -20.35M -22.25M -17.78M -13.83M
Other operating expenses 18.71M 20.35M 22.31M 17.92M 13.99M
Interest expense - - - 0.25M 0.12M
Tax provision 0.86M 0.54M 0.14M 0.09M 0.00M
Interest income 0.24M 0.36M 0.49M 0.38M -
Net interest income 0.24M 0.36M 0.55M 0.38M 0.01M
Income tax expense 0.86M 0.54M 0.08M 0.09M 0.00M
Total revenue 0.00M 0.00M 0.06M 0.14M 0.16M
Total operating expenses 18.62M 20.35M 22.31M 17.92M 13.99M
Cost of revenue 0.09M 0.08M 0.08M - -
Total other income expense net -0.59M 0.48M 0.06M 0.28M -0.06M
Net income from continuing ops -20.16M -20.41M -22.22M -17.59M -13.89M
Net income applicable to common shares - - - -17.59M -13.89M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 22.82M 12.12M 18.61M 24.10M 38.99M
Intangible assets 0.10M 0.13M 0.19M 0.21M 0.20M
Other current assets 0.60M 0.45M 0.74M 0.85M 0.73M
Total liab 4.25M 4.78M 6.03M 5.22M 4.17M
Total stockholder equity 18.56M 7.34M 12.58M 18.88M 34.82M
Other current liab 2.31M 2.44M 2.16M 2.11M 1.40M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -101.36M -81.19M -60.78M -38.52M -20.93M
Other liab - - - 0.16M 0.33M
Other assets - - - 0.05M 0.05M
Cash 20.84M 10.39M 11.79M 7.31M 36.88M
Total current liabilities 3.35M 3.91M 4.95M 4.13M 2.55M
Current deferred revenue - 0.25M 1.12M 0.06M 0.27M
Net debt -20.11M -9.73M -10.77M -6.04M -35.27M
Short term debt 0.22M 0.27M 0.35M 0.34M 0.32M
Short long term debt 0.10M 0.11M 0.12M 0.11M 0.10M
Short long term debt total 0.73M 0.65M 1.03M 1.27M 1.61M
Other stockholder equity 119.14M 88.78M 73.11M 57.36M 55.83M
Property plant equipment - - - 0.14M 1.01M
Total current assets 22.24M 11.60M 17.78M 21.09M 37.72M
Long term investments - - 0.00M 1.94M -
Net tangible assets - - - 18.67M 34.61M
Short term investments - 0.00M 5.00M 12.83M -
Net receivables 0.80M 0.77M 0.24M 0.10M 0.11M
Long term debt 0.30M 0.33M 0.45M 0.50M 0.59M
Accounts payable 0.83M 0.95M 1.32M 1.63M 0.56M
Accumulated other comprehensive income 0.78M -0.25M 0.25M 0.04M -0.09M
Common stock total equity - - - 0.00M -
Retained earnings total equity - - - -20.93M -
Non currrent assets other 0.03M 0.03M 0.02M 0.05M 0.05M
Non current assets total 0.58M 0.52M 0.83M 3.01M 1.26M
Capital lease obligations 0.33M 0.21M 0.46M 0.67M 0.91M
Long term debt total - - - 0.50M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 4.98M 7.21M -14.66M -0.09M
Change to liabilities - - - 0.86M -0.49M
Total cashflows from investing activities - 4.98M 10.22M -14.77M -0.09M
Net borrowings -0.10M -0.09M -0.09M -0.08M -0.02M
Total cash from financing activities 28.45M 13.01M 12.64M -0.08M 41.77M
Change to operating activities - - - 0.66M 0.15M
Net income -20.16M -20.41M -22.27M -17.59M -13.89M
Change in cash 10.46M -1.41M 4.49M -29.57M 29.41M
Begin period cash flow 10.42M 11.83M 7.34M 36.91M 7.50M
End period cash flow 20.87M 10.42M 11.83M 7.34M 36.91M
Total cash from operating activities -18.47M -18.87M -18.87M -14.69M -12.37M
Issuance of capital stock 25.47M 13.21M 3.15M 0.00M 42.63M
Depreciation 0.09M 0.08M 0.08M 0.06M 0.02M
Change to inventory - - - - 0.09M
Change to account receivables - - -0.13M 0.00M 0.01M
Other cashflows from financing activities - -0.11M 12.73M -14.77M -0.84M
Change to netincome - - - 1.32M 1.84M
Capital expenditures 0.00M 0.02M 0.02M 0.12M 0.09M
Cash flows other operating - - - 1.51M -
Cash and cash equivalents changes - - - -29.55M -
Change in working capital -1.01M -1.08M 0.44M 1.51M -0.39M
Stock based compensation 1.80M 2.39M 3.26M 1.53M 0.84M
Other non cash items 0.80M 0.14M -0.38M -0.21M -0.03M
Free cash flow -18.47M -18.90M -18.88M -14.81M -12.46M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GANX
Gain Therapeutics Inc		 -0.08
7.21%		 1.03 - - 255.50 6.76 138.33 -1.55
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Gain Therapeutics Inc

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

4800 Montgomery Lane, Bethesda, MD, United States, 20814

301 500 1556

https://gaintherapeutics.com

20

Name Title Year Born
Dr. Khalid Islam Ph.D. Founder & Chairman 1955
Mr. Matthias Alder LIC. IUR., LL.M. COO, CEO & Director 1965
Mr. Salvatore Calabrese CFO & Corp. Sec. 1970
Dr. Xavier Barril Ph.D. Chief Technology Officer NA
Dr. Manolo Bellotto Ph.D. GM & Chief Strategy Officer 1971
Dr. Ana Maria Garcia-Collazo Ph.D. Head of Research NA
Dr. Natalia Perez-Carmona Ph.D. Head of Biology NA
Dr. Joanne Taylor Ph.D. Sr. VP of Research & Scientific Advisor NA
Dr. Terenzio Ignoni Pharm.D. Sr. VP of Technical Operations NA
Mr. Matthias Alder LIC. IUR., LL.M. President, CEO & Director 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…